imatinib mesylate has been researched along with Adenomatous Polyposis Coli in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balaguer, F; Ocaña, T; Olivas, P; Pellisé, M; Tobon, A | 1 |
| Gräter, H | 1 |
| Fujimori, Y; Hara, H; Hirota, S; Ishikawa, H; Itsukuma, T; Kai, S; Misawa, M; Nakagawa, K; Sugihara, A; Terada, N | 1 |
| Ezumi, K; Ikeda, M; Monden, M; Nomura, M; Sekimoto, M; Takemasa, I; Yamamoto, H | 1 |
1 review(s) available for imatinib mesylate and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
[Tumors of the small intestine].
Topics: Adenocarcinoma; Adenoma; Adenomatous Polyposis Coli; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Diagnosis, Differential; Duodenal Neoplasms; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Risk | 2002 |
3 other study(ies) available for imatinib mesylate and Adenomatous Polyposis Coli
| Article | Year |
|---|---|
Imatinib: a new chemopreventive option in adenomatous polyposis?
Topics: Adenomatous Polyposis Coli; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2020 |
Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Dacarbazine-Doxorubicin therapy ameliorated an extremely aggressive mesenteric desmoid tumor associated with familial adenomatous polyposis: report of a case.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dacarbazine; Doxorubicin; Fibromatosis, Aggressive; Humans; Imatinib Mesylate; Male; Mesentery; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Piperazines; Pyrimidines; Remission Induction; Tamoxifen | 2008 |